Home Alzheimer’s Disease ASCO Expert Discusses Clinical Benefit of Combination for Relapsed/Refractory Multiple Myeloma

ASCO Expert Discusses Clinical Benefit of Combination for Relapsed/Refractory Multiple Myeloma

Ajay K. Nooka, MD, MPH, FACP, an ASCO expert from the Winship Cancer Institute of Emory University, discussed the clinical benefit of belantamab mafodotin in combination with bortezomib plus dexamethasone combination treatment for relapsed/refractory multiple myeloma presented at the 2020 ASCO Virtual Scientific Program.

Transcription:

What about the clinical benefit or the clinical efficacy? The overall response rate that was seen with this combination was 78%. The clinical benefit rate was seen in 83% which is—4 out of 5 people go on to benefit from this combination. More importantly you’re able to see the depth of response, the VGPR range greater than 50% with this combination. This is all in alignment with a prior 3-drug combination with the specific backbone of bortezomib/dexamethasone and with the manageable safety profile. From my perspective to conclude, it has a great…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

My Brain Tumor Taught Me To Shift My Perspective on These 5 Things

submitted by /u/andrewjoegeorge Continue Reading to the Source

Recent Comments